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Abstract. The aim of this study is to investigate the dissolution properties of poorly
soluble drugs from their pure form and their amorphous formulation under physiological
relevant conditions for oral administration based on surface dissolution ultraviolet (UV)
imaging. Dissolution of two poorly soluble drugs (cefuroxime axetil and itraconazole) and
their amorphous formulations (Zinnat® and Sporanox®) was studied with the Sirius Surface
Dissolution Imager (SDI). Media simulating the fasted state conditions (compendial and
biorelevant) with sequential media/ﬂow rate change were used. The dissolution mechanism
of cefuroxime axetil in simulated gastric ﬂuid (SGF), fasted state simulated gastric
ﬂuid (FaSSGF) and simulated intestinal ﬂuid (SIF) is predominantly swelling as opposed to
the convective ﬂow in fasted state simulated intestinal ﬂuid (FaSSIF-V1), attributed to the
effect of mixed micelles. For the itraconazole compact in biorelevant media, a clear upward
diffusion of the dissolved itraconazole into the bulk buffer solution is observed. Dissolution
of itraconazole from the Sporanox® compact is affected by the polyethylene glycol (PEG)
gelling layer and hydroxypropyl methylcellulose (HPMC) matrix, and a steady diffusional
dissolution pattern is revealed. A visual representation and a quantitative assessment of
dissolution properties of poorly soluble compounds and their amorphous formulation can be
obtained with the use of surface dissolution imaging under in vivo relevant conditions.
KEY WORDS: surface dissolution; UV imaging; poorly soluble drugs; amorphous formulation; intrinsic
dissolution; biorelevant dissolution.
INTRODUCTION
The amorphous form has attracted increasing interest
within the pharmaceutical ﬁeld because its higher solubility
could achieve better dissolution rate and absorption rate and
increase the bioavailability of poor water-soluble compounds
(1). The solubility increment of amorphous forms over
crystalline states depends on the potential energy difference
between these physical states (2,3). It was estimated that 10–
1600 folds of solubility increment can be achieved by applying
the amorphous form (4).
From the physical stability point of view, the drug which
is formulated in an amorphous state should be preserved and
stabilised to exert its solubility advantage even during the
dissolution process (5). There are only a handful of oral
pharmaceutical products containing amorphous active phar-
maceutical ingredient (API) that have been successfully
marketed despite several decades of effort in research and
development; examples include cefuroxime axetil (CA) (6),
itraconazole (ITR) (7), quinapril (8), etravirine (9),
zaﬁrlukast (10) and rosuvastatin (11). The limited commercial
success indicates the challenges with the stability of the
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amorphous formulations (12). One of the issues relating to
the stability of the amorphous state is its solution-mediated
transformation characteristic. Solution-mediated transforma-
tion of amorphous to crystalline state is the conversion of
metastable solids such as amorphous solids to the crystalline
state when the solids are exposed to a solvent. The
transformation to the more thermodynamically stable crys-
talline state occurs at a higher rate because of the higher
mobility in the solution state than in the solid. In drug process
development, characterisation of solution-mediated transfor-
mations in the amorphous state is important because it
describes information on amorphous crystallisation (13).
For poorly water-soluble drugs, the maximum achiev-
able intraluminal drug concentration may limit absorption.
However, the intraluminal concentration of a drug is not
necessarily limited by its solubility in gastrointestinal ﬂuids
(14). Drugs may be in solution at a concentration above their
saturation solubility, that is, in a state of supersaturation. A
supersaturated drug solution is thermodynamically unstable
compared to the equilibrium condition (saturation). Thus, it
has the tendency to return to the equilibrium state (lowest
chemical potential) by drug precipitation (15). The higher
the supersaturation, the more precipitation will take place as
the former is the driving force for the latter (16). This higher
initial solubility may be sufﬁcient to ensure increased and
more rapid absorption for a drug with good permeability
such as Biopharmaceutical Classiﬁcation System (BCS) class
1 and 2 compounds. But, a more thermodynamically stable
form may crystallise at any time inside the gastrointestinal
(GI) tract and the crystallisation would have a major impact
on the product performance in vivo (17). The higher
dissolution rate and apparent solubility of an amorphous
drug usually cause supersaturation during in vivo dissolution.
Therefore, this may lead to precipitation in the GI tract (as
the supersaturation is the driving force for the precipitation)
and compromise oral bioavailability (14).
In the GI tract, drug solubility can be enhanced by food and
bile components such as bile salts, lecithin and fatty acids.
Supersaturation in the intestinal ﬂuid is an important property
that can play a signiﬁcant role in drug absorption. For compounds
with poor intrinsic solubility in the intestinal ﬂuid, solubility is
often a limiting factor for absorption. For many of these
compounds, it may not be possible to enhance the saturation
solubility to the extent required such that the whole dose is
dissolved in the GI ﬂuid. In this case, creating or maintaining
supersaturation in the intestinal ﬂuid can be an effective way to
enhance the absorption of these compounds (18).
Surface ultraviolet (UV) dissolution imaging is very useful
in characterising active compounds and their formulations, as
the captured images illustrate the concentration distribution of
drug compounds, which can be translated into the amount and
rate of drug dissolution (19–24). The surface UV dissolution
imaging is applicable as most pharmaceutical drug substances
contain a UV chromophore. The intensity of the measured light
is converted to absorbance, creating a high-resolution, real-time
2D absorbance and concentration map of dissolution events
within the ﬂow cell which presents a detailed view of the
dissolution process occurring on the surface of the drug compact
(25). The data can then be processed for measurement of the
intrinsic dissolution rate (IDR) of the active compound (pure
API or formulation), with the whole process typically taking
around 20 min (26,27). The ActiPix™ SDI300 is a multipurpose
UVarea imaging system which enables quantitative imaging of
surface dissolution for various applications such as pure active
compound (19,21,23), transdermal patch (20), crystal (22,28),
gels (29,30), polymer (31), cocrystal (32–34), excipient shielding
(35), salt (36), drug-phospholipid complexes (37), oral strip ﬁlm
(38) and oily liquid (39). Using this system, temporal and high-
resolution spatial data from the solid–liquid interface can be
observed. Measurement of this dissolution process has been
described in length in the literature (19,22,25,29), and it offers
insight into surface events such as boundary layer thickness,
surface concentration, contour distribution, concentration gra-
dient proﬁles and surface changes from swelling or gelling. The
ActiPix™ SDI300 also supplies special insights into processes
occurring in microns to millimetres from the surface, the crucial
distance range for recognising dissolution. Moreover, the
dissolution medium can be changed easily (for example, from
simulated gastric ﬂuid to simulated intestinal ﬂuid) that will
reveal the effect of medium (pH and buffer) and hydrodynamics
(ﬂow rate) to the precipitation and dissolution of the tested
compound. The resulting images with media change setup may
increase the understanding of the in vivo dissolution process,
which may also increase the predictive ability of this dissolution
test method. Owing to the fact that the ﬂow-cell volume is small,
the time to produce the ﬂow rate changes is relatively short. For
example, the ﬂow rate can go from high velocity (4 mL/min)
down to no velocity (static, 0 mL/min) almost instantly.
Similarly, the low volume also means that less dissolution
medium is required, and it is cost-effective when biorelevant
media are used. The dissolution setup is very useful for
screening potential drug compounds during the pre-
formulation stages because the intrinsic dissolution rates can
be obtained in less than 20 min compared to 24-h equilibrium
IDR using the traditional dissolution system (Wood apparatus).
In this study, two BSC class 2 amorphous compounds
(CA and ITR) and their amorphous formulations (Zinnat®
and Sporanox®, respectively) were used. The study aimed to
investigate the dissolution properties of these poorly soluble
compounds from their pure form and their amorphous
formulation based on surface dissolution UV imaging under
physiological relevant conditions for oral administration. The
surface of the samples was exposed to media simulating the
fasted state conditions: compendial (simulated gastric ﬂuid
(SGF) and simulated intestinal ﬂuid (SIF)) and biorelevant
(fasted state simulated gastric ﬂuid (FaSSGF) and fasted state
simulated intestinal ﬂuid (FaSSIF-V1)) media with sequential
media/ﬂow rate change. Biorelevant dissolution media have
been used in previous UV dissolution imaging studies
(23,40,41) to characterise drug dissolution. To the best of
our knowledge, our study is the ﬁrst study in which an
experimental design using media and ﬂow rate change is
applied in the UV dissolution imaging.
MATERIALS AND METHODS
Materials
Sporanox® capsules (Janssen-Cilag, Ltd., Bucks, UK)
and Zinnat® tablets (GlaxoSmithKline, Middlesex, UK) were
purchased commercially. ITR standard (98% w/w) (batch no.
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097K1156; St. Louis, MO), CA standard (United States
Pharmacopeia (USP) Reference Standard, Lot 09822G;
Rockville, MD), amorphous ITR API (intrinsic solubility
0.001 μg/mL) and amorphous CA API (intrinsic solubility
0.4 μg/mL) were provided by Hoffmann-La Roche, Nutley
USA.
Glyceryl monooleate (GMO; Rylo M19 Pharma®, 99.5%
monoglyceride) was a gift from Danisco A/S, Grindsted,
Denmark. Egg phosphatidylcholine (Lipoid E PC®) was
generously donated by Lipoid GmbH, Ludwigshafen,
Germany. Sodium oleate (lot number SZBB0110V) and
sodium chloride (NaCl) were purchased from Sigma-Aldrich
(Dorset, UK). Sodium taurocholate (NaTC, 97% pure) was
purchased from Prodotti Chimici e Alimentari S.p.A.,
Basaluzzo, Italy. The Milli-Q water was obtained from a
Nanopure® Diamond UF and UV/UF Water Barnstead
System (Thermo Scientiﬁc, Dubuque, USA). Buffer compo-
nents were analytical grade.
Preparation of Compendial and Biorelevant Media
A fasted state simulating gastric ﬂuid without pepsin
(SGF) (42) and fasted state simulating intestinal ﬂuid without
pancreatin (SIF) (42) were used to simulate the fasting gastric
and intestinal composition, respectively (43,44). Biorelevant
media simulating the conditions in the gastric and intestinal
environment in the fasted state (FaSSGF and FaSSIF-V1,
respectively) were prepared according to the procedure
described by Vertzoni et al. (45,46).
Preparation of Compacts
Compacts were prepared using ITR (4 mg) and CA
(4 mg) reference standard powder, Sporanox® pellet (4 mg;
the hard gelatin Sporanox capsule was removed beforehand)
and grounded Zinnat® tablet powder (4 mg; Zinnat® tablet
was grounded into ﬁne powder using a mortar and pestle).
Samples were transferred into a stainless steel cylinder
sample cup (2 mm inner diameter × 2.4 mm height). A
Quickset Minor® torque screwdriver (Torqueleader; M.H.H.
Engineering Co., Ltd., England) was used to compress the
weighted materials at a constant torque pressure of 0.6 Nm
for 1 min.
Surface Dissolution UV Imaging
Sirius SDI (model name: ActiPix™ SDI300; Sirius
Analytical Instruments, East Sussex, UK) utilises ActiPix™
UV area imaging technology combined with a laminar ﬂow-
through sample holder, an integrated syringe pump and the
software. The device consists of a pulsed xenon lamp
(PerkinElmer, Waltham, MA) with personal computer inter-
face control box, a remote UV camera sensor with ﬁbre optic
cable, a band-pass ﬁlter (wavelength 214 nm, 254 nm or
280 nm) and a CADISS-2 dissolution cartridge. The
CADISS-2 comprises of a 62-mm rectangular quartz tube,
Luer Lock connector ﬂow-cell inlet and outlet as well as a
cartridge body. Either the 20-mL and 50-mL BD plastic
buffer delivery syringes were used to hold the dissolution
medium. Detection was performed at 280 nm (band width
10 nm). The utilised CADISS-2 quartz ﬂow cell had a light
path of 4 mm. The imaging system consists of 1280 × 1024
pixels with dimensions of 9 mm2 × 7 mm2 (total imaging area
of 9 mm2 × 7 mm2), and each pixel can be considered as a
conventional single-beam spectrophotometer. Output from
the sensor is connected to a computer at a rate of one
snapshot every 0.5 s for processing and storage. A syringe
pump (RS-232 integrated pump; Maxim Integrated Products,
Inc., USA) was used for infusion of dissolution media at
constant and changing ﬂow rates, with temperature controlled
at 37°C using a Techne DB-2D Dri-Block® digital heater
(Staffordshire, UK). Dissolution experiments were performed
using ITR and CA reference standard, Sporanox® and
Zinnat® compacts, as described below.
Media and Flow Rate
Constant Flow Rate Studies
The ﬂow rates in the ActiPix™ ﬂow cell corresponding
to the nominal physiological linear velocity of the ﬂuid in the
stomach (2 cm/min) and intestine (1 cm/min) (47) were
determined using the following linear relationship: y =
7.17x − 0.0135 (R2 = 0.999) (the linear regression of linear
velocity of the ActiPix™ ﬂow-through cell [cm/min] versus
various ﬂow rates [mL/min]). Without taking into account the
cross-sectional water loss, the calculated ﬂow rates of the
ActiPix™ ﬂow cell are 0.28 mL/min and 0.14 mL/min for the
stomach and intestine conditions, respectively (48). Further-
more, to complement the dataset of the ﬂow rate range
between 0 and 1.0 mL/min, two bridging ﬂow rates of 0.6 mL/
min and 1.0 mL/min were also used for these studies
(Table I).
Flow Rate Change Studies
Based on the fact that both the ActiPix™ ﬂow cell and
USP apparatus 4 ﬂow-through cell provide unilateral laminar
ﬂow and lower turbulence within the ﬂow cell, a one-tenth
magnitude scale-down of the corresponding USP apparatus 4
setup was used (49,50). Hence, ﬂow rates of 0.8 mL/min and
0.4 mL/min (reﬂecting the conditions in the human stomach
and intestine, respectively) were used in the experiment with
media and ﬂow rate change (Table I).
Experimental Conditions
The experimental conditions for the studies with surface
dissolution UV imaging are described in Table I. Constant
ﬂow rate denotes a study using a single dissolution medium
under the ﬂow rates of 0.14 mL/min, 0.28 mL/min, 0.4 mL/
min, 0.6 mL/min, 0.8 mL/min and 1 mL/min whereas the
media and ﬂow rate change denotes a study using, ﬁrstly,
gastric medium (ﬂow rate 0.8 mL/min) and then intestinal
medium (ﬂow rate 0.4 mL/min). Experiments were performed
in triplicate unless otherwise indicated, and each run lasted
24 min.
Calibration curves were constructed by ﬂowing drug
standard solutions through the dissolution cell at a ﬂow rate
of 1 mL/min. Recording of UV images was performed when
each of the standard solutions was infused for a period of
5 min. The buffer was infused before and after the series of
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reference standard solutions for 4 min in order to detect
baseline drift. The standard solutions were prepared using
CA and ITR reference standard in FaSSGF and SGF,
respectively. The concentration range used for both CA and
ITR was 5–180 μg/mL; FaSSGF was chosen for CA due to its
low degradation in this medium, and SGF was chosen for ITR
due to its relatively good solubility in this medium (51). Three
UV readings were made at different time points at each
concentration, and the average values were used for the
calibration plot. The interference caused by the bile salts of
FaSSGF or polymer of the solid dispersion was minimum as
indicated by the similar absorbance recorded in standard
solutions without bile salt and polymers. In each experiment,
buffer solution was used to calibrate the spectrophotometer
so that any absorbance attributable to the bile salts and
polymer as well as particle on the compact surface can be
compensated. By setting the absorbance of the blank to zero,
an instrumental subtraction measures only the drug absor-
bance. The collected data were then used to calculate
dissolution rates and cumulative amount dissolved of tested
compounds in the various media at 1-min intervals, using
ActiPix™ D100 software, version 1.5 (York, England)
(20,51).
RESULTS AND DISCUSSION
Surface Dissolution UV Imaging of Cefuroxime Axetil
An initial dissolution test using Zinnat® (amorphous
formulation of CA) compact was not satisfactory because the
high loading of super-disintegrant croscarmellose sodium in
Zinnat® became a dense layer after being exposed to the
dissolution medium (51). This layer caused physical blocking
of the light and yielded a large amount of debris that clogged
the ﬂow cell, thus preventing further testing of this amor-
phous formulation of CA (51).
Single Medium and Constant Flow Rate Study
The IDR results of CA pure API in compendial and
biorelevant media (constant media) versus time proﬁles under
various ﬂow rates are presented in Fig. 1.
As observed from the results of the individual constant ﬂow
rate studies (ﬂow rate of 1 mL/min, 0.8 mL/min, 0.6 mL/min,
0.4 mL/min, 0.28 mL/min and 0.14 mL/min), the effect of ﬂow rate
on the CA IDR proﬁles is evident (Fig. 1). A clear stepwise IDR
reduction in tandem with a ﬂow rate decrease (of each individual
constant ﬂow rate experiments) is revealed in FaSSIF-V1.
A compilation of all measured IDR results versus ﬂow
rate is shown in Fig. 2. The graph proﬁles for the studies in
SGF, FaSSGF and SIF are almost straight lines and suggest
that the dissolution rate is almost constant independent of the
ﬂow rate, whereas, with the FaSSIF-V1 proﬁles, the graph
proﬁle shows an apparent gradient which indicates dissolution
in convective ﬂow as the main dissolution mechanism. This
observation is a good indicator of the effect of mixed micelles
that facilitate and enhance the dissolution of poorly water-
soluble compounds (52,53). All IDR proﬁles, regardless of
the media used, yielded a plateau IDR versus time proﬁle
which reveals zero-order release kinetics with a constant drug
release rate over a period of time. This indicates that sink
conditions for CA dissolution possibly exist in the channel
ﬂow cell that would be of importance for the simulation of the
in vivo conditions (26,48). Comparing speciﬁcally with
an amorphous furosemide formulation reported elsewhere
(41), several similarities were observed. Firstly, a larger area
of intense absorbance was observed at the compact surface;
secondly, precipitated drug was washed down from the
compact surface; and thirdly, absorbant ‘tail’ was observed
downstream from the surface of the compact (41).
Media and Flow Rate Change Study
Dissolution behaviour of CA was monitored by the
surface dissolution UV imaging in SGF (0.8 mL/min; 6 min)
Table I. Periods During Which the Compact Was Exposed to the Dissolution Media and the Flow Rate that Each Medium Was Pumped
Through the Cell
Medium Period of each ﬂow rate (min) Flow rate (mL/min)
ITR and CA pure API compact
Constant ﬂow rate
SGF/FaSSGF/SIF#/FaSSIF-V1 5 for gastric media 0.14, 0.28, 0.4, 0.6, 0.8, 1
15 for intestinal media
Media and ﬂow rate change
SGF/FaSSGF 0–6 0.8
SIF/FaSSIF-V1 7–24 0.4
Sporanox® pellet compact*
Constant ﬂow rate
SGF#/FaSSGF/SIF/FaSSIF-V1 5 for gastric media 0.14, 0.28, 0.4, 0.6, 0.8, 1
15 for intestinal media
Media and ﬂow rate change
SGF/FaSSGF 0–6 0.8
SIF/FaSSIF-V1 7–24 0.4
*Experiments with Zinnat® compact were not successful due to the presence of a superdisintegrant in the formulation
#Data for Sporanox® pellet compact in SGF with a flow rate of 0.6 mL/min and ITR API compact in SIF with a flow rate of 1.0 mL/min are not
available
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followed by SIF (0.4 mL/min; 18 min). The UV images of
absorbance maps of dissolved CA at selected time points are
shown in Fig. 3. A contour concentration line is presented in
the concentration scale bar. All concentrations were lower
than 35 μg/mL (within the linear range of the calibration
curve). Dissolution occurs as a result of both convection and
diffusion, as reported also in other studies (22,23,29,39,54).
The absorbance contours reveal that laminar ﬂow conditions
are prevailing in the ﬂow cell, while the thickness of the
downstream tail varies with the ﬂow rate, similar to what has
been shown previously (22,23,29,39,54).
After media and ﬂow rate change, the drug concentra-
tion peak at 8 min forms a supersaturated solution and then
gradually reduces. An apparent turbulent pattern contour is
observed which could probably imply a dispersion of the
recrystallised particle at 8 min and 10 min corresponding to
the crystal growth post supersaturation (as indicated by the
arrow in Fig. 3). The measured dissolution layer thickness at
the surface is approximately 0.05 mm to 0.1 mm under both
ﬂow rates (0.8 mL/min and 0.4 mL/min), whereas the
calculated dissolution layer thickness is 4.34 mm × 10−3 mm
under 0.8 mL/min and 8.66 mm × 10−3 mm under 0.4 mL/min
(51).
On another note, the measured dissolution layer thick-
ness values using surface UV imaging apparatus are far
higher than the calculated dissolution layer thickness. Ac-
cording to the literature (55), this phenomenon suggests that
CA dissolved from the surface as aggregate, initially forming
a supersaturated solution; this is in agreement with the
observed IDR and amount of CA dissolved from the pure
API compact with media and ﬂow rate change from SGF
(0.8 mL/min) to SIF (0.4 mL/min) (Fig. 4). Figure 4 indicates
that there are two supersaturated solutions formed in SGF
and SIF before particle precipitation and decrease of IDR.
Drug supersaturation, which often precedes precipitation, is
conventionally determined in vitro through solubility and
solution concentration comparison. A recent study conducted
using UV-vis imaging, light microscopy and Raman spectros-
copy has characterised the piroxicam supersaturation, precip-
itation and dissolution in an enclosed ﬂow-through casing
(15). A study by Sun et al. (15) is different as crystalline drug
and dissolved drug were inserted instead of the API or
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Fig. 1. Mean ± SD IDR of CA from its pure API compact in the compendial and biorelevant media (n = 3)
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formulation that was used in the present study. Our study also
reveals that hydrodynamic conditions such as ﬂow rate and
ﬂow pattern inﬂuence the rate and extent of drug precipita-
tion (15). Furthermore, swelling, crystal growth and/or
precipitation at the compact surface can be detected as it
has also been shown for the metastable forms of amlodipine
besylate where the amorphous salt, the crystalline anhydrate
and dihydrate salt forms as well as the amlodipine free base
were conﬁrmed (21).
Surface Dissolution UV Imaging of Itraconazole
Single Medium and Constant Flow Rate Study
The IDR results of ITR from ITR pure API and
Sporanox® compacts in compendial and biorelevant media
versus time proﬁles are presented in Fig. 5. A stepwise
decrease in dissolution rate corresponding to the stepwise
reduction in ﬂow rate is obtained from the imaging data
(Fig. 5). This trend is expected based on the convective
diffusion theory (56). The key parameter in convective
diffusion theory is the concentration at the surface (57). The
impact of reducing the ﬂow rate from 1 to 0.14 mL/min on the
IDR proﬁles was evident in ITR pure API in the compendial
and biorelevant media and Sporanox® formulation in SGF
and FaSSIF-V1. In Sporanox®, the IDR proﬁles in FaSSGF
and SIF showed no obvious rank order, probably due to the
interference of surface dissolution characterisation in the
presence of excipients and polymers, such as hydroxypropyl
methylcellulose (HPMC) and polyethylene glycol (PEG). In
order to determine the dissolution mechanism of ITR from
both compacts, the IDR results were plotted against the ﬂow
rate (Fig. 6).
Comparing with analysis using the MRI ﬂow-cell
dissolution setup using amorphous felodipine (58), slow
erosion of compacted material due to the consolidation of
the matrix on compression was also observed in our study.
The close resemblance of the ﬂow-cell setup allowed us to
indicate that supersaturated drug solution occurred in the
proximity of the solid–liquid interface caused by the
relatively slow erosion of the compacted materials under
the conditions of low convection employed. In agreement
with the ﬁndings presented by Langham et al. (58),
nucleation and growth of solid drug particles were driven
by the supersaturated solutions.
The dissolution mechanism of ITR from Sporanox®
compact (SIF and FaSSIF-V1 at 1 mL/min) showed a
steeper curve than from the pure API compact. This is in
agreement with the dissolution kinetics of ITR
characterised with USP apparatus 4, showing that the
dissolution in convective ﬂow is the main process in
determining the dissolution of ITR formulated as a solid
dispersion–coating pellet (51). The IDR trends in
biorelevant media did not reveal the advantage of the
surfactants in terms of enhancing the dissolution rate. This
is because bile salt has been shown to potentially undergo
an acid–base reaction with ITR molecules, leading to
slower ITR dissolution (52,53).
The HPMC content in Sporanox® pellet coating is 60%
w/w (ratio of 1:1.5 ITR to HPMC); thus, at this high
concentration, the release of ITR is controlled by HPMC.
The multiparticulate drug–coated Sporanox® pellet is also
coated with the PEG membrane at its outer most layer (7).
The rate of ITR dissolution is dependent not only on the
thickness of the membrane but also on the composite of the
HPMC-ITR solid solution matrix itself which sustains the
dissolution (59). Furthermore, HPMC has a gelling property
upon hydration which has been identiﬁed as a variable
affecting drug dissolution (60). Hence, the dissolution of
ITR from Sporanox® compact was delayed due to drug
particles having to diffuse out from the HPMC matrix before
undergoing dissolution.
Legend 
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media (n = 3)
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Due to the poor solubility of ITR in SIF and without
the interference of bile salt and lecithin, SIF was able to
discriminate Sporanox® formulation (amorphous
formulation) and ITR pure API (crystalline compact),
with the IDR of ITR from Sporanox® pellet compact in
SIF being nearly ten times higher than the one from pure
API compact. The results seem to suggest that this
experiment setup and conditions could be used to
discriminate critical manufacturing variables of such
formulations.
Media and Flow Rate Change Study
Dissolution behaviour of ITR from its pure API and
Sporanox® compacts were monitored by the surface UV
dissolution apparatus in the sequential change of compendial
media (SGF [0.8 mL/min; 6 min] followed by SIF [0.4 mL/
min; 18 min]) and in the sequential change of biorelevant
media (FaSSGF [0.8 mL/min; 6 min] followed by FaSSIF-V1
[0.4 mL/min; 18 min]). The IDR and cumulative amount of
ITR dissolved are presented in Fig. 7.
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Fig. 4. Mean ± SD IDR of CA dissolved from its pure API compact
in SGF (0.8 mL/min; 6 min)/SIF (0.4 mL/min; 18 min) (n = 2). Blue
arrow indicates time with media change
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horizontal arrows indicate turbulent pattern contour potentially caused by dispersion of the recrystallised particle
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Compared to the ﬂat and linear proﬁles in single
media (SGF, SIF, FaSSGF and FaSSIF-V1; Fig. 7), the
proﬁles with media change have exhibited their own
characteristic gradient. In the dissolution proﬁles of exper-
iments with media change using surface dissolution UV
imaging, a biphasic curve is apparent, with a sudden
increment after media change from the simulated gastric
medium to the simulated intestinal medium. A higher
supersaturation ratio could be observed with the media
change from FaSSGF to FaSSIF-V1, due to micellar
solubilisation. The same dissolution rate enhancement was
observed for the Sporanox® pellet compact in the
biorelevant setup (FaSSGF/FaSSIF-V1) but not in the
compendial one (SGF/SIF).
The IDR proﬁle of ITR from the pure API compact in
SGF/SIF and FaSSGF/FaSSIF-V1 showed that after me-
dium and ﬂow rate changes from simulating gastric
condition to simulating intestinal condition, the IDR and
amount dissolved increased signiﬁcantly, forming a tran-
sient supersaturated solution of ITR. After 5 min to 8 min,
the supersaturation ratio reduced steadily toward the
equilibrium dissolution rate of 0.128 mg/min/cm2 in
FaSSIF-V1 and 0.051 mg/min/cm2 in SIF, yielding a total
amount of ITR dissolved of 98 μg and 51 μg, respectively.
The higher ITR dissolution expected from the amorphous
formulation compact was not revealed probably due to the
interaction of bile salt (found in FaSSIF-V1) and potassium
salt (found in SIF) with PEG (61). The PEG coating used
in Sporanox® pellet to prevent agglomeration hinders the
ITR dissolution in the surface dissolution UV imaging; this
was also shown in the ITR proﬁles from Sporanox®
compacts in the constant biorelevant media (FaSSGF and
FaSSIF-V1) study (Fig. 7).
The concentration curves of ITR dissolved from ITR
pure API compact and Sporanox® pellet compact relative
to the compact surface axis are presented as concentration
contours within the UV absorbance maps of ITR dissolved
at different selected time points (Fig. 8). The contours of
Sporanox® pellet compacts (Fig. 8) show that density
gradients in the proximity of compact surface affect the
concentration distribution of the surrounding solutions.
Accumulation of dissolved ITR was slightly skewed
toward the left part of the contour images for the sample
due to a higher density of the HPMC and PEG gel matrix
as compared to the solvent. As discussed previously, ITR
dissolution from the Sporanox® compact is affected by the
PEG gelling layer and HPMC matrix. On the other hand,
the contour of ITR pure API compact shows a ﬂat and
broad laminar layer. ITR pure API compact in FaSSGF/
FaSSIF-V1 forms the least concentrated solution in the
dissolution layer compared with the studies in SGF/SIF and
also compared to the studies of the Sporanox® compact.
There was a clear upward movement of the dissolved ITR
into the bulk buffer solution as the downstream distance
increases to form a stable dissolution layer. Furthermore,
the distorted curve and abnormal shifting of contour lines
observed strongly indicate that ITR dissolution is followed
by recrystallisation of the ITR particle at the compact
surface (black bold arrow in Fig. 8). In the studies using
pure API compact with compendial media, although a
thicker dissolution layer is observed throughout the whole
experiment, the size of the dissolution layer quickly
dissipates to the minimum layer at 18 min. In the ITR
pure API compact studies with biorelevant media, there
was a signiﬁcant decrease in the dissolution layer after
10 min of the dissolution test that slowly relaxed at a low
concentration layer. It could be concluded that the fast
supersaturation formed on the surface after media change
drastically increased the recrystallisation of ITR on the
surfaces of the compacts which could also lead to crystal
growth on the surface. A similar setup to examine
nilotinib, a protein kinase inhibitor formulated as an
amorphous solid dispersion has been reported (27). Com-
pared to the study conducted by Colombo et al. (27),
solution-mediated phase transformation did not occur to
ITR from Sporanox® compact in the beginning of this
experiment. ITR from Sporanox® compact precipitated at
the later stage of the experiment, conﬁrming that
precipitation of an amorphous compound was avoided
due to high drug load that prevented matrix swelling
during media change (27).
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CONCLUSIONS
Surface dissolution UV imaging methodology that could
be used to understand the mechanism of CA and ITR (pure
APIs and their amorphous formulations) dissolution was
developed in this project. From the surface dissolution UV
imaging testing, the UV images of absorbance maps and
contour concentration lines of the dissolved CA during the
studies with media and ﬂow rate change (SGF/SIF) revealed
that CA dissolved from the compact surface as aggregates
and formed a supersaturated CA solution that subsequently
precipitated out. Similarly, for ITR, the supersaturation of
ITR after media change drastically increased the
recrystallisation of ITR on the surfaces of the ITR pure API
and Sporanox® compacts which could lead to ITR crystal
growth. The UV images obtained from these studies provided
a visual representation and a qualitative as well as
quantitative assessment of the differences in dissolution
rates and concentration for the model compounds used.
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